{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:01:55Z","timestamp":1782126115709,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by a Colorado Department of Public Health and Environment Research Grant."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cannabis is commonly used as a self-prescribed treatment for anxiety and depression, but few studies have evaluated these associations using both validated mental health scales and biological cannabinoid markers. This study aimed to test associations between cannabis use frequency and symptoms of anxiety and depression, and to examine whether frequent cannabis users with high symptom scores were less likely to use FDA-approved medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a secondary analysis of a cross-sectional study on sleep and cannabis use, including 195 participants who completed the Hospital Anxiety and Depression Scale (HADS), Beck Anxiety Inventory (BAI), Beck Depression Inventory-II (BDI-II), and self-reported cannabis use. Urinary tetrahydrocannabinol (THC) metabolites validated recent cannabis exposure. Regression models adjusted for demographic and clinical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Frequent cannabis use (\u2265\u200915 uses in the past 30 days) vs. infrequent use (14 or fewer uses in the past 30 days) was associated with higher likelihood of anxiety, AOR\u2009=\u20091.06 (95% CI 1.01, 1.12),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01 for the BAI and AOR\u2009=\u20091.05 (95% CI 1.01, 1.09),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 for the HADS-A. However, frequency of cannabis use was not associated with depression for either the HADS-D, AOR\u2009=\u20090.98 (95% CI 0.94, 1.05) or BDI-II, AOR\u2009=\u20090.98 (95% CI 0.92, 1.04),\n                      <jats:italic>ps<\/jats:italic>\n                      \u2009&gt;\u20090.05. Use of FDA-approved anxiolytic or antidepressant medications did not significantly differ by non-use, infrequent, and frequent cannabis use groups (20% vs. 18.2% vs. 21.1% for anxiolytic-hypnotics and 14% vs. 9.1% vs. 11.4% for antidepressants), and urinary cannabinoid levels were not associated with symptom severity, all\n                      <jats:italic>ps<\/jats:italic>\n                      \u2009&gt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated anxiety was common among frequent cannabis users, yet use of FDA-approved medications was infrequent in this group despite increased symptom burden. These results suggest that some individuals may turn to cannabis to manage their symptoms instead of using evidence-based treatments. Clinicians should consider the possibility that patients might substitute cannabis for prescription medications, and routinely screen cannabis users for untreated anxiety. Randomized studies are needed to determine causal associations between anxiety symptoms and cannabis use, including potential interactions with FDA-approved pharmacotherapies. Such evidence will inform clinical recommendations and policy on cannabis use and mental health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-025-00327-2","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:00:52Z","timestamp":1760702452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Frequency of cannabis use and symptoms of anxiety and depression: a cross-sectional analysis of the Colorado cannabis users health cohort"],"prefix":"10.1186","volume":"7","author":[{"given":"Christine M.","family":"Steeger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poojashree","family":"Tandukar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin F.","family":"Hoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Aloia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Wamboldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Castaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Lorenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Crotty Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost","family":"Klawitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sempio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Kinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan D.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina R.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell P.","family":"Bowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"327_CR1","doi-asserted-by":"crossref","unstructured":"Althoff MD, Kinney GL, Aloia MS, Sempio C, Klawitter J, Bowler RP. (2024). The impact of cannabis use proximal to sleep and cannabinoid metabolites on sleep architecture. Journal of Clinical Sleep Medicine, jcsm. 11212.","DOI":"10.5664\/jcsm.11212"},{"key":"327_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jpsychires.2020.07.030","volume":"129","author":"A Bahji","year":"2020","unstructured":"Bahji A, Meyyappan AC, Hawken ER. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis. J Psychiatr Res. 2020;129:257\u201364. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.07.030.","journal-title":"J Psychiatr Res"},{"key":"327_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jad.2017.02.016","volume":"213","author":"AL Bahorik","year":"2017","unstructured":"Bahorik AL, Leibowitz A, Sterling SA, Travis A, Weisner C, Satre DD. Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord. 2017;213:168\u201371. https:\/\/doi.org\/10.1016\/j.jad.2017.02.016.","journal-title":"J Affect Disord"},{"key":"327_CR4","doi-asserted-by":"publisher","unstructured":"Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety, Post-Traumatic Stress O-C, Zohar D, Hollander J, Kasper E, Moller S, Bandelow HJ, Allgulander B, Ayuso-Gutierrez C, Baldwin J, Buenvicius DS, Cassano R, Fineberg G, Gabriels N, Vega L. J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9(4):248\u2013312. https:\/\/doi.org\/10.1080\/15622970802465807","DOI":"10.1080\/15622970802465807"},{"key":"327_CR5","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown GK. BDI-II, Beck depression inventory: manual. 2nd ed. Psychological Corp.; 1996.","DOI":"10.1037\/t00742-000"},{"issue":"1","key":"327_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000534855","volume":"7","author":"A Beletsky","year":"2024","unstructured":"Beletsky A, Liu C, Lochte B, Samuel N, Grant I. Cannabis and anxiety: A critical review. Med Cannabis Cannabinoids. 2024;7(1):19\u201330.","journal-title":"Med Cannabis Cannabinoids"},{"issue":"1","key":"327_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00213-002-1144-9","volume":"163","author":"F Berrendero","year":"2002","unstructured":"Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology. 2002;163(1):111\u20137. https:\/\/doi.org\/10.1007\/s00213-002-1144-9.","journal-title":"Psychopharmacology"},{"issue":"1","key":"327_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42238-024-00250-y","volume":"6","author":"R Bhuller","year":"2024","unstructured":"Bhuller R, Schlage WK, Hoeng J. Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of Cannabidiol. J Cannabis Res. 2024;6(1):1\u201323.","journal-title":"J Cannabis Res"},{"issue":"4","key":"327_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1089\/can.2023.0187","volume":"9","author":"LC Bidwell","year":"2024","unstructured":"Bidwell LC, Martin-Willett R, Skrzynski C, Lisano J, Ortiz Torres M, Giordano G, Hutchison KE, Bryan AD. Acute and extended anxiolytic effects of Cannabidiol in cannabis flower: A quasi-experimental ad libitum use study. Cannabis Cannabinoid Res. 2024;9(4):1015\u201327.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"327_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","volume":"52","author":"I Bjelland","year":"2002","unstructured":"Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res. 2002;52(2):69\u201377.","journal-title":"J Psychosom Res"},{"key":"327_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/SAR.S109576","volume":"8","author":"U Bonnet","year":"2017","unstructured":"Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9\u201337. https:\/\/doi.org\/10.2147\/SAR.S109576.","journal-title":"Subst Abuse Rehabil"},{"key":"327_CR12","doi-asserted-by":"publisher","unstructured":"Bradford AC, Bradford WD. (2016). Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. https:\/\/www.healthaffairs.org\/doi\/https:\/\/doi.org\/10.1377\/hlthaff.2015.1661","DOI":"10.1377\/hlthaff.2015.1661"},{"issue":"6","key":"327_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0006-3223(95)00188-3","volume":"39","author":"N Breslau","year":"1996","unstructured":"Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39(6):411\u20138. https:\/\/doi.org\/10.1016\/0006-3223(95)00188-3.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"327_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds III, Monk CF, Berman TH, S. R., Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193\u2013213.","journal-title":"Psychiatry Res"},{"key":"327_CR60","doi-asserted-by":"crossref","unstructured":"Caulkins JP, Pardo B, Kilmer B. Intensity of cannabis use: Findings from three online surveys. Int J Drug Policy. 2020;79:102740.","DOI":"10.1016\/j.drugpo.2020.102740"},{"key":"327_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00406-019-00983-5","volume":"269","author":"S Chandra","year":"2019","unstructured":"Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008\u20132017). Eur Arch Psychiatry Clin NeuroSci. 2019;269:5\u201315.","journal-title":"Eur Arch Psychiatry Clin NeuroSci"},{"key":"327_CR16","unstructured":"Colorado Department of Public Health and Environment (CDPHE). (2020). Medical marijuana statistics and data. Retrieved 8 Oct 2024, from https:\/\/cdphe.colorado.gov\/medical-marijuana-registry-data"},{"key":"327_CR64","doi-asserted-by":"crossref","unstructured":"Corroon Jr JM, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs\u2013a cross-sectional study. J Pain Res. 2017:989\u2013998.","DOI":"10.2147\/JPR.S134330"},{"key":"327_CR17","doi-asserted-by":"publisher","first-page":"102207","DOI":"10.1016\/j.ctim.2019.102207","volume":"47","author":"JM Doremus","year":"2019","unstructured":"Doremus JM, Stith SS, Vigil JM. Using recreational cannabis to treat insomnia: evidence from over-the-counter sleep aid sales in Colorado. Complement Ther Med. 2019;47:102207.","journal-title":"Complement Ther Med"},{"key":"327_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jad.2014.10.006","volume":"172","author":"D Feingold","year":"2015","unstructured":"Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and mood disorders: A longitudinal study. J Affect Disord. 2015;172:211\u20138.","journal-title":"J Affect Disord"},{"issue":"5","key":"327_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1177\/0269881109106910","volume":"24","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2010","unstructured":"Garc\u00eda-Guti\u00e9rrez MS, Manzanares J. The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines. J Psychopharmacol. 2010;24(5):757\u201365.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"327_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamapsychiatry.2018.4500","volume":"76","author":"G Gobbi","year":"2019","unstructured":"Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76(4):426\u201334.","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"327_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/brainsci13020325","volume":"13","author":"A Hasbi","year":"2023","unstructured":"Hasbi A, Madras BK, George SR. Endocannabinoid system and exogenous cannabinoids in depression and anxiety: A review. Brain Sci. 2023;13(2):325.","journal-title":"Brain Sci"},{"issue":"3","key":"327_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.slsci.2015.09.002","volume":"8","author":"C Hirotsu","year":"2015","unstructured":"Hirotsu C, Tufik S, Andersen ML. Interactions between sleep, stress, and metabolism: from physiological to pathological conditions. Sleep Sci. 2015;8(3):143\u201352. https:\/\/doi.org\/10.1016\/j.slsci.2015.09.002.","journal-title":"Sleep Sci"},{"key":"327_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","volume":"51","author":"R Jetly","year":"2015","unstructured":"Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585\u20138. https:\/\/doi.org\/10.1016\/j.psyneuen.2014.11.002.","journal-title":"Psychoneuroendocrinology"},{"issue":"Suppl 11","key":"327_CR25","doi-asserted-by":"publisher","first-page":"S467","DOI":"10.1002\/acr.20561","volume":"63","author":"LJ Julian","year":"2011","unstructured":"Julian LJ. Measures of anxiety: State-Trait anxiety inventory (STAI), Beck anxiety inventory (BAI), and hospital anxiety and depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S467\u2013472. https:\/\/doi.org\/10.1002\/acr.20561.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"327_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/7854_2009_9","volume":"2","author":"RC Kessler","year":"2010","unstructured":"Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top Behav Neurosci. 2010;2:21\u201335. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21309104.","journal-title":"Curr Top Behav Neurosci"},{"key":"327_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42238-019-0012-y","volume":"2","author":"R Khan","year":"2020","unstructured":"Khan R, Naveed S, Mian N, Fida A, Raafey MA, Aedma KK. The therapeutic role of Cannabidiol in mental health: A systematic review. J Cannabis Res. 2020;2:1\u201321.","journal-title":"J Cannabis Res"},{"issue":"5","key":"327_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/FTD.0000000000000427","volume":"39","author":"J Klawitter","year":"2017","unstructured":"Klawitter J, Sempio C, Morlein S, De Bloois E, Klepacki J, Henthorn T, Leehey MA, Hoffenberg EJ, Knupp K, Wang GS, Hopfer C, Kinney G, Bowler R, Foreman N, Galinkin J, Christians U, Klawitter J. An atmospheric pressure chemical ionization MS\/MS assay using online extraction for the analysis of 11 cannabinoids and metabolites in human plasma and urine. Ther Drug Monit. 2017;39(5):556\u201364. https:\/\/doi.org\/10.1097\/FTD.0000000000000427.","journal-title":"Ther Drug Monit"},{"key":"327_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.socscimed.2019.06.005","volume":"233","author":"JD Kosiba","year":"2019","unstructured":"Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med. 2019;233:181\u201392.","journal-title":"Soc Sci Med"},{"key":"327_CR65","doi-asserted-by":"crossref","unstructured":"Kvamme SL, Pedersen MM, R\u00f8mer Thomsen K, Thylstrup B. Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample. Harm Reduct J. 2021;18(1):72.","DOI":"10.1186\/s12954-021-00520-5"},{"key":"327_CR68","doi-asserted-by":"crossref","unstructured":"Lamoureux-Lamarche C, Berbiche D, Vasiliadis HM. Health care system and patient costs associated with receipt of minimally adequate treatment for depression and anxiety disorders in older adults. BMC psychiatry. 2022;22(1):175.","DOI":"10.1186\/s12888-022-03759-9"},{"issue":"2","key":"327_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.chest.2022.04.151","volume":"162","author":"I Lavender","year":"2022","unstructured":"Lavender I, McGregor IS, Suraev A, Grunstein RR, Hoyos CM. Cannabinoids, insomnia, and other sleep disorders. Chest. 2022;162(2):452\u201365.","journal-title":"Chest"},{"issue":"2","key":"327_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/add.14459","volume":"114","author":"BJ Leadbeater","year":"2019","unstructured":"Leadbeater BJ, Ames ME, Linden-Carmichael AN. Age\u2010varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults. Addiction. 2019;114(2):278\u201393.","journal-title":"Addiction"},{"key":"327_CR61","doi-asserted-by":"crossref","unstructured":"Lorenzetti V, Hindocha C, Petrilli K, Griffiths P, Brown J, Castillo\u2010Carniglia \u00c1, et al. The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use. Addiction. 2021;117(6):510\u20131517","DOI":"10.1111\/add.15702"},{"issue":"2","key":"327_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/00952990.2023.2299922","volume":"50","author":"DJ Lowe","year":"2024","unstructured":"Lowe DJ, Sorkhou M, George TP. Cannabis use in adolescents and anxiety symptoms and disorders: a systematic review and meta-analysis. Am J Drug Alcohol Abus. 2024;50(2):150\u201361.","journal-title":"Am J Drug Alcohol Abus"},{"key":"327_CR66","doi-asserted-by":"crossref","unstructured":"Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30\u201335.","DOI":"10.1016\/j.drugpo.2017.01.011"},{"issue":"12","key":"327_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrn4036","volume":"16","author":"B Lutz","year":"2015","unstructured":"Lutz B, Marsicano G, Maldonado R, Hillard CJ. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015;16(12):705\u201318.","journal-title":"Nat Rev Neurosci"},{"key":"327_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.euroneuro.2024.11.007","volume":"91","author":"G Martinotti","year":"2025","unstructured":"Martinotti G, Di Forti M. Cannabis use and psychosis: evidence and new clinical features of a new epidemic. Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacol. 2025;91:45\u20136.","journal-title":"Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacol"},{"key":"327_CR35","unstructured":"National Institute of Mental Health (NIMH). (2017). Statistics. Retrieved 10 Dec 2024, from www.nimh.nih.gov\/health\/statistics"},{"key":"327_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jad.2020.12.043","volume":"281","author":"VN Onaemo","year":"2021","unstructured":"Onaemo VN, Fawehinmi TO, D\u2019Arcy C. Comorbid cannabis use disorder with major depression and generalized anxiety disorder: A systematic review with meta-analysis of nationally representative epidemiological surveys. J Affect Disord. 2021;281:467\u201375.","journal-title":"J Affect Disord"},{"key":"327_CR37","unstructured":"Orens AD. Marketing size and demand for marijuana in Colorado 2017, market update. Marijuana Policy Group; 2018."},{"issue":"4","key":"327_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1037\/pha0000126","volume":"25","author":"LR Pacek","year":"2017","unstructured":"Pacek LR, Herrmann ES, Smith MT, Vandrey R. Sleep continuity, architecture and quality among treatment-seeking cannabis users: an in-home, unattended polysomnographic study. Exp Clin Psychopharmacol. 2017;25(4):295.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"Pt A","key":"327_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neubiorev.2016.12.033","volume":"76","author":"S Patel","year":"2017","unstructured":"Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A. The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev. 2017;76(Pt A):56\u201366. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.12.033.","journal-title":"Neurosci Biobehav Rev"},{"issue":"7374","key":"327_CR40","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/bmj.325.7374.1195","volume":"325","author":"GC Patton","year":"2002","unstructured":"Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195\u20138. https:\/\/doi.org\/10.1136\/bmj.325.7374.1195.","journal-title":"BMJ"},{"issue":"9","key":"327_CR41","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S2215-0366(22)00161-4","volume":"9","author":"K Petrilli","year":"2022","unstructured":"Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: A systematic review. Lancet Psychiatry. 2022;9(9):736\u201350.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"327_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/CXA.0000000000000124","volume":"12","author":"GL Polkosnik","year":"2021","unstructured":"Polkosnik GL, Sorkhou M, George TP. Effects of cannabis use on psychotic and mood symptoms: a systematic review. Can J Addict. 2021;12(3):10\u201321.","journal-title":"Can J Addict"},{"key":"327_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brat.2018.11.008","volume":"115","author":"MA Prince","year":"2019","unstructured":"Prince MA, Conner BT. Examining links between cannabis potency and mental and physical health outcomes. Behav Res Ther. 2019;115:111\u201320.","journal-title":"Behav Res Ther"},{"key":"327_CR44","doi-asserted-by":"publisher","first-page":"106991","DOI":"10.1016\/j.addbeh.2021.106991","volume":"121","author":"J Rup","year":"2021","unstructured":"Rup J, Freeman TP, Perlman C, Hammond D. Cannabis and mental health: prevalence of use and modes of cannabis administration by mental health status. Addict Behav. 2021;121:106991.","journal-title":"Addict Behav"},{"key":"327_CR45","doi-asserted-by":"publisher","unstructured":"Scherma M, Masia P, Deidda M, Fratta W, Tanda G, Fadda P. New perspectives on the use of cannabis in the treatment of psychiatric disorders. Med (Basel). 2018;5(4). https:\/\/doi.org\/10.3390\/medicines5040107.","DOI":"10.3390\/medicines5040107"},{"issue":"1","key":"327_CR46","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12967-020-02518-2","volume":"18","author":"L Sharpe","year":"2020","unstructured":"Sharpe L, Sinclair J, Kramer A, De Manincor M, Sarris J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Translational Med. 2020;18(1):374.","journal-title":"J Translational Med"},{"key":"327_CR62","doi-asserted-by":"crossref","unstructured":"Sofis MJ, Budney AJ, Stanger C, Knapp AA, Borodovsky JT. Greater delay discounting and cannabis coping motives are associated with more frequent cannabis use in a large sample of adult cannabis users. Drug Alcohol Depend. 2020;207:107820.","DOI":"10.1016\/j.drugalcdep.2019.107820"},{"key":"327_CR47","doi-asserted-by":"publisher","first-page":"630247","DOI":"10.3389\/fpsyt.2021.630247","volume":"12","author":"M Sorkhou","year":"2021","unstructured":"Sorkhou M, Bedder RH, George TP. The behavioral sequelae of cannabis use in healthy people: A systematic review. Front Psychiatry. 2021;12:630247.","journal-title":"Front Psychiatry"},{"key":"327_CR48","doi-asserted-by":"publisher","first-page":"1346207","DOI":"10.3389\/fpubh.2024.1346207","volume":"12","author":"M Sorkhou","year":"2024","unstructured":"Sorkhou M, Dent EL, George TP. Cannabis use and mood disorders: A systematic review. Front Public Health. 2024;12:1346207.","journal-title":"Front Public Health"},{"issue":"3","key":"327_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.31887\/DCNS.2003.5.3\/lstaner","volume":"5","author":"L Staner","year":"2003","unstructured":"Staner L. Sleep and anxiety disorders. Dialogues Clin Neurosci. 2003;5(3):249\u201358. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22033804.","journal-title":"Dialogues Clin Neurosci"},{"key":"327_CR50","doi-asserted-by":"publisher","first-page":"103278","DOI":"10.1016\/j.drugpo.2021.103278","volume":"97","author":"CM Steeger","year":"2021","unstructured":"Steeger CM, Hitchcock LN, Bryan AD, Hutchison KE, Hill KG, Bidwell LC. Associations between self-reported cannabis use frequency, potency, and cannabis\/health metrics. Int J Drug Policy. 2021;97:103278.","journal-title":"Int J Drug Policy"},{"key":"327_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drugpo.2016.11.010","volume":"42","author":"SR Sznitman","year":"2017","unstructured":"Sznitman SR. Do recreational cannabis users, unlicensed and licensed medical cannabis users form distinct groups? Int J Drug Policy. 2017;42:15\u201321.","journal-title":"Int J Drug Policy"},{"key":"327_CR52","doi-asserted-by":"publisher","first-page":"152188","DOI":"10.1016\/j.comppsych.2020.152188","volume":"102","author":"J Turna","year":"2020","unstructured":"Turna J, Balodis I, Munn C, Van Ameringen M, Busse J, MacKillop J. Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. Compr Psychiatr. 2020;102:152188.","journal-title":"Compr Psychiatr"},{"issue":"11","key":"327_CR53","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/da.22664","volume":"34","author":"J Turna","year":"2017","unstructured":"Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017;34(11):1006\u201317. https:\/\/doi.org\/10.1002\/da.22664.","journal-title":"Depress Anxiety"},{"issue":"11","key":"327_CR54","doi-asserted-by":"publisher","first-page":"zsac218","DOI":"10.1093\/sleep\/zsac218","volume":"45","author":"R Velzeboer","year":"2022","unstructured":"Velzeboer R, Malas A, Boerkoel P, Cullen K, Hawkins M, Roesler J, Lai WW-K. Cannabis dosing and administration for sleep: A systematic review. Sleep. 2022;45(11):zsac218.","journal-title":"Sleep"},{"issue":"2","key":"327_CR55","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.pbb.2005.01.029","volume":"81","author":"MP Viveros","year":"2005","unstructured":"Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005;81(2):331\u201342. https:\/\/doi.org\/10.1016\/j.pbb.2005.01.029.","journal-title":"Pharmacol Biochem Behav"},{"key":"327_CR56","doi-asserted-by":"publisher","unstructured":"Wallis D, Coatsworth JD, Mennis J, Riggs NR, Zaharakis N, Russell MA, Brown AR, Rayburn S, Radford A, Hale C, Mason MJ. Predicting Self-Medication with cannabis in young adults with hazardous cannabis use. Int J Environ Res Public Health. 2022;19(3). https:\/\/doi.org\/10.3390\/ijerph19031850.","DOI":"10.3390\/ijerph19031850"},{"key":"327_CR63","doi-asserted-by":"crossref","unstructured":"Walsh CA, Euler E, Do LA, Zheng A, Eckel SP, Harlow BL, et al. Cannabis use and sleep problems among young adults by mental health status: A prospective cohort study. Addiction. 2025;120(4):688\u2013696.","DOI":"10.1111\/add.16705"},{"key":"327_CR67","doi-asserted-by":"crossref","unstructured":"Weisberg RB, Beard C, Moitra E, Dyck I, Keller MB. Adequacy of treatment received by primary care patients with anxiety disorders. Depression and Anxiety. 2014;31(5):443\u2013450.","DOI":"10.1002\/da.22209"},{"issue":"9","key":"327_CR57","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.4088\/JCP.14m09475","volume":"76","author":"ST Wilkinson","year":"2015","unstructured":"Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174\u201380. https:\/\/doi.org\/10.4088\/JCP.14m09475.","journal-title":"J Clin Psychiatry"},{"issue":"5\u20136","key":"327_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/00008877-200509000-00005","volume":"16","author":"JM Witkin","year":"2005","unstructured":"Witkin JM, Tzavara E, Nomikos G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol. 2005;16(5\u20136):315\u201331.","journal-title":"Behav Pharmacol"},{"issue":"6","key":"327_CR59","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x.","journal-title":"Acta Psychiatr Scand"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-025-00327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-025-00327-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-025-00327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:40:59Z","timestamp":1781613659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42238-025-00327-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1186\/s42238-025-00327-2","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the National Jewish Health Institutional Review Board (IRB). All participants in the study sample consented to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}